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Executive Summary
This paper examines the characteristics of venture-funded medical device companies that
were successfully acquired, and their valuation at acquisition. It analyzes the impact of
different factors of the investors, the investment timing, the intellectual property obtained
by the start-up and the capital market environment, on the valuation of the firm at the
time of acquisition. Specifically, it was hypothesized that the following factors are
associated with the deal value:
Figure 1: Hypotheses
For the analysis, I built a database using deal transaction data from VenturXpert, and
other data from SDC Thomson Financials, Compustat, press releases and the US Patent
Office website. I filtered the deals to include the Venture Economics classifications of
Medical/Health Products, Medical Diagnostics, and Medical Therapeutics, for deals that
were announced from January1998 to April 2006. After eliminating duplicate entries and
deals for which data was not disclosed or available, a total of 90 deals were identified for
analysis.
The summary of data for this sample of
acquired is shown in Figure 2.
start up companies that succeeded in getting
Mean Median Std Dev Max Min
Transaction Value (Constant 2006 $) ($MM) $ 147 $ 91 $ 207 $1,291 $ 0.4
Total Investment (Constant 2006 $) ($MM) $ 36 $ 29 $ 34 $ 191 $ 0.3
Years since first investment 5.6 5.3 3.3 16.9 0.7
Number of Investors 6.2 5 4.2 18 1
Number of investing rounds 4.5 4 3.0 11 1
Valuation to Investment ratio (Unadjusted) 25.4 3.8 116.8 1053.0 0
Valuation to Investment ratio (Constant 2006 $) 22.7 3.54 103.9 936.7 0.03
Number of Patents 15.1 7.0 20.5 86.0 0
Figure 2: Characteristics of Targets at Acquisition
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There were Corporate Venture Capital investments in 26 of the 90 target companies that
were acquired (29%), and 16 (17%) of these companies were already public.
A multi-variate linear regression analysis was done on the data, looking at the transaction
value as the dependent variable. The factors that were analyzed were able to explain 27%
of the variation in deal value for the total data set. The Results of the analysis are shown
in Figure 3.
Statistically Significant?
Term Estimate P Value At 95% CL At 70% CL
Target Current Public Status[Public] (44.77) 0.13 No Yes
Corporate Venture Capital?[Yes] 30.78 0.22 No Yes
Years since first investment 29.72 <.0001 Yes Yes
Number of Investors (10.07) 0.21 No Yes
Num. of investing rounds (5.64) 0.56 No No
Infl. Adj total investmt ($MM) 0.891 0.27 No Yes
Dow Jones Med Eq 0.354 0.20 No Yes
Number of Patents 0.305 0.78 No No
NASDAQ Composite 0.025 0.76 No No
Max. size of investing firm 0.012 0.00 Yes Yes
Rounds Experience of Investor (0.001) 0.57 No No
S&P 500 (0.001) 1.00 No No
Figure 3: Regression Analysis Results
The two factors that had a surprising impact on valuation were the Target's public status
and the number of investors. Private companies were on average, associated with a
higher deal value ($45 MM) than public companies (p value= 0.13). This went against the
hypothesis that companies that had already gone public would attract higher valuations
because of better governance systems and transparency. The second surprising result was
that the number of investors was negatively associated with the valuation (p value=0.21).
Most of the other hypotheses were supported at different levels of statistical significance.
Having a corporate investor funding the company is associated with higher valuation.
Larger investors are associated with statistically significant increases in valuation. The
most significant impact is that of the "years since first funded", which suggests that
companies are rewarded for the added risks and costs of developing their technologies
further. These effects are captured in the regression analysis done in this thesis. I
conclude that start-up companies should carefully review their options regarding their
investors and the stage to which they develop technologies before acquisition, based on
their firm specific risks and costs, as those decisions have a discernible impact on exit
valuation.
Introduction
In the medical device space, a large proportion of the breakthrough inventions are
developed by small firms that use private equity to bring their technologies from concept
to varying stages of development. Medical Device companies spend a large proportion
(11.4 % in 2002) of their sales on R&D, second only to Pharmaceutical companies.
Smaller companies, in the meanwhile, spent 343 % of their sales in the same year'. [The
Lewin Group (AdvaMed), 2004].
Private Equity financing is a critical factor that enables small start-ups to develop new
technologies without a viable revenue stream to support the necessary R&D expenditure.
In the medical device space, it has been noted that Venture Capital firms (VC's) use high
risk capital to invest in early stage companies, and look for "exits" through either an
Initial Public Offering (IPO) or through the sale of the start-up to an established firm.
Corporations are also involved in varying degrees in early venture investments, through
what is sometimes called Corporate Venture Capital (CVC), mainly for strategic reasons.
Through CVC investments, some corporations hope, that as an insider, they would be
able to judge better whether a particular company is a good target for acquisition.
In this paper I review the exits through acquisition, from the perspective of venture
backed start-ups, and hypothesize that factors related to the nature of investors, the type
of investment, the impact of capital markets and the Intellectual Property of the company
are associated with a higher exit valuation.
This paper is organized as following. First, I review the medical device industry, the
market segmentation, size and growth forecasts, and the leading Medical Device
manufacturers. The next section discusses Medical Device start-ups and the typical
development and commercialization pathway. The hypotheses are laid out next, along
with the methodology of the analysis planned, and then each factor is discussed
individually. Finally, we look at the results of the analysis, the limitations of the study,
and draw conclusions.
Motivation
The topic of this paper was chosen due to my interest in the medical device space, and
from my interaction with my thesis advisors, Dr. Rox Anderson, Director of the Wellman
Center of Photomedicine at the Massachusetts General Hospital (MGH), and with Dr.
Jonathan Rosen, Director of Technology Implementation, Center for Integration of
Medicine and Innovative Technology (CIMIT).
A promising technology based on the next generation Optical Coherence Tomography
(OCT), called Optical Frequency Domain Imaging is being developed by Dr. Gary
Tearney and his group at the Wellman Center, for specific applications including GI tract
imaging. The MGH licensing office, called the office of Corporate Sponsored Research
& Licensing (CSRL), CIMIT, which had funded part of the project, and the Project team
were evaluating the different options to take the development of this technology forward.
These discussions, some of which I was involved in, revolved around how long the
project should be financed internally within MGH (Partners Healthcare), when the start-
up should be out looking for external funding, how long an exit would take, how much
money is typically raised, what are the ranges of deal values at acquisitions and so on.
While many practitioners in the field have rules of thumb regarding valuation, a
preliminary review of the literature showed a lack of published data specific to venture
backed medical device acquisitions. Hence, I undertook the research and analysis
presented in this thesis.
Statement on Conflict of Interest: There are no conflicts of interest that I am aware of in
this study.
Medical Devices
The Center for Devices and Radiological Health at the Food and Drug Administration,
the major regulatory body in the United States, defines2 a medical device as:
"A device is an instrument, apparatus, implement, machine, contrivance, implant, in vitro
reagent, or other similar or related article, including a component part, or accessory which
is:
recognized in the official National Formulary, or the United States Pharmacopoeia, or
any supplement to them,
intended for use in the diagnosis of disease or other conditions, or in the cure,
mitigation, treatment, or prevention of disease, in man or other animals, or
intended to affect the structure or any function of the body of man or other animals,
and which does not achieve any of it's primary intended purposes through chemical
action within or on the body of man or other animals and which is not dependent upon
being metabolized for the achievement of any of its primary intended purposes."
The medical device industry has played a key role in the advancement of medical care
around the world. Products like pacemakers, defibrillators, insulin pumps, laparoscopic
devices for minimally invasive surgery, orthopedic implants and more accurate
diagnostic techniques that are able to detect diseases earlier have transformed the health
care system, dramatically improving patient outcomes and speeding recovery time.
Market Size and Growth Rate
Figure 4: International Markets for the Medical Devices and Diagnostics Industry
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The Medical Device industry includes a wide variety of products from some decidedly
low-tech "durable medical equipment" (DME) like bed pans to high technology products
like pacemakers. Generally, the industry is analyzed by each category separately, and it
is difficult to obtain recent data on the entire space. A report in the Medical Device
Technology Journal 3 in 2004, says that the US Medical equipment market is projected to
grow by 8% between 2001 and 2006, to reach $105 billion in 2006. The Advanced
Medical Technology Association (AdvaMed), is the main trade association of medical
device companies, and has laid out some illuminating data through it medical technology
report, 2004'. It reports that the US market size was $72 Billion dollars in 2000,
accounting for about 43 % of the world market. The growth rate in the US and the
different parts of the world is shown in Figure 4. The Rest of the world, including
markets in Asia, Latin America and Eastern Europe show the highest growth rates, due in
part due to the relatively small base that they currently have (-8% of the world market).
The global market, according to the same report, has been growing at a fair paced clip of
10.6% during the period 1991-1996.
I I
Following is data taken from DataStream of the Dow Jones Medical Equipment Index
(Developed markets) compared with the S&P 500 and the NASDAQ composite index.
With a compounded annual growth rate (CAGR) of 14% percent, it is clear that the
Medical Devices Market has vastly outperformed the broader stock market in recent
years.
- DJ ME
S&P 500
NASD
0
Figure 5: Dow Jones Medical Equipment Index vs. Other Indices
(Source: DataStream)
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Market Place Segmentation
Figure 6: US Device Industry Segmentation (Source: Frost & Sullivan)
The US Medical Device industry can be segmented in many ways. Figure 6 has been
compiled from data in a report titled "Medical Devices Market Outlook" May, 2005,
from the market research firm Frost & Sullivan. It should be noted, that since 2002 many
new technologies, including drug eluting stents, that have seen a huge growth in the
market have been introduced that are not adequately represented in this table.
Below, I briefly describe the major segments, in terms of the products it includes.
[Source: Frost & Sullivan]
Cardiovascular devices are the largest segment in the medical devices market
accounting for about 23% of the total medical devices market. This market includes drug
eluting and bare metal stents, angioplasty devices, heart valves and pacemakers.
Orthopedic Equipment is the second largest segment, and includes joint implants such
as hip and knee implants, and spine care products.
Wound Care and Management includes the traditional wound dressings, and a growing
number of advanced therapies such as moist, interactive, and antimicrobial dressings.
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Surgical Instruments: Laser and electrosurgery devices are the fast growing groups
identified in this segment.
Neurology Equipment has the neurostimulation segment which is forecasted to grow at
a high rate
Drug Delivery and infusion systems segment is dominated by needles, syringes, and
medication solutions. The high growth areas are implantable drug and insulin infusion
pumps.
Ophthalmic Equipment includes contact lenses and LASIK surgeries.
Hearing Aids include technologically programmable and non programmable
technologically advanced hearing aids including cochlear implants.
Respiratory and Anesthesia Equipment market accounted for roughly 1.7 percent of
the total U.S. medical device market revenues in 2004.
Endoscopy Systems: The total endoscopy market, includes visualization equipment such
as cameras light sources, monitors VCR's and digital recorders, and scopes,
Infection Control: Includes products such as gloves, drapes and other disinfection and
Sterilization Equipment.
Durable Medical Equipment is a very broad segment including bedpans, crutches,
wheel chairs and other mobility aids, and fitness equipment.
Biomaterials and Hemostats: The major biomaterials market today include hyaluronic
acid and collagen.
Miscellaneous: As defined by Frost & Sullivan, this included urological, dental and renal
(Dialysis Equipment) market groups. The dialysis equipment market accounted for
roughly 3.3 percent of the total U.S. medical device market revenues in 2004 ($2.09 B).
Another major segment that is apparently not covered in the report above is the glucose
monitoring segment, which is estimated to be greater than $4 BN dollars in the US, in
2005.
Leading Medical Device Companies
The leading Medical devices companies by revenue [Frost & Sullivan, 2004]4 are shown
in Figure 7.
Figure 7: List of Top Medical Device
Companies by Revenue.
(Source: Frost and Sullivan)
Of the top medical devices companies, most are "pure plays" in a few segments of the
medical device industries. The notable exceptions are Johnson & Johnson and Baxter
Healthcare, which have products beyond medical devices, while Becton Dickinson has
broad product lines across many medical device segments. Also of note, nine of the top
ten medical device companies in the world are U.S. based.
_ _ ~
Medical Device Start-ups
Generally, larger medical device companies have been successful in developing and
commercializing incremental improvements of current devices. But, the development of
breakthrough medical innovations and technologies are generally brought forth by
venture-backed start-up companies. "Typically, a physician and/or engineer inventor
conceives of a device solution to an unmet clinical challenge, initiates the patent process,
and builds preliminary device prototypes. Preliminary bench and animal testing may be
performed using the inventor's or an acquaintance's personal funding (angel investors).
Further development typically requires engaging a team of engineers who work closely
with physician advisors to bring the concept through the "design-build-test-redesign"
cycle of bench and animal testing. This preclinical stage typically takes 2 to 3 years and
depending on the nature of the device may consume US$10 to $20 million before the
device is ready for clinical testing. These capital requirements exceed the means of most
angel syndicates and are typically obtained from venture capital firms in the form of
equity financing." [Kaplan et al, 2004].
Figure 8 shows the number of companies that have less than 20 employees in the industry
compared to the medium and larger established ones [The Lewin Group, AdvaMed
2004].
Figure 8: Size Distribution of Medical Device Companies (2001)
(Source: AdvaMed/US Department of Commerce)
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Development and Regulatory Approval Process
The Center for Devices and Radiological Health (CDRH) division of the FDA is
responsible for the regulation of medical devices in the US. For regulatory purposes,
devices are classified according their perceived risk level into Class I, II or III (increasing
risk levels).
Most Class I devices are exempt from Premarket Notification 510(k); most Class II
devices require Premarket Notification 510(k); and most Class III devices require
Premarket Approval (PMA)5. A premarket notification or 510(K) must demonstrate
"substantial equivalence" to another approved device that is called the "predicate" device.
A premarket approval, an actual approval of the device by the FDA, is required for Class
III devices that "pose a significant risk of illness or injury" or those "found not
substantially equivalent to Class I and II predicate though the 510(k) process. These
devices are generally life-sustaining/supporting, of substantial importance in preventing
impairment of human health. Kaplan et al give an excellent review of the typical steps
that a start-up has to go through in order to get through the regulatory hurdles and the
investor required mile stones, for a class III device. Approval of the PMA requires
clinical data demonstrating reasonable assurance that the device is safe and effective in
the target population. Clinical testing of an unapproved significant-risk medical device
requires FDA approval in the form of an Investigational Device Exemption (IDE). The
IDE application provides information to the FDA on device design and qualification, as
well as on the study protocol. First Clinical use is a key milestone for any technology,
and companies, seeking the quickest path, generally shift (>75%) this testing outside the
US. First Clinical Use testing, when done within the US, are rarely (<25%) done at large
academic institutions, due to the bureaucracy associated for IRB (Institutional Review
Board) approval.
Clinical development of a new class III device is typically divided into pilot and pivotal
trial phases. The purpose of the pilot phase (starting with first clinical use) is to establish
safety and to assist in design of the pivotal trial. Pilot-phase testing is typically limited to
fewer than 100 patients treated at a few centers. The purpose of the pivotal trial is to
generate data that define patient populations in which use of the device is safe and
effective. [Kaplan, et al, 2004]
4 ý
Maisel ["Medical Device Regulation"- Maisel 2004], also explains in simple terms the
steps that go into the approval of a medical device, in Figure 9.
Figure 9: Medical Device Approval Process (Source: Maisel 2004)
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Venture Capital
Venture Capital has been defined in the finance world as "the investment by professional
investors of long-term, unquoted, risk equity finance in new firms, where the primary
reward is an eventual capital gain..." [Wright and Robbie, 1998]. Venture Capitalists
concentrate investments in early stage and high technology companies where information
asymmetries are highest. [Gompers, 1995]. Gompers and Lerner (2001)6 give a good
account of the evolution of the venture capital industry, from the American Research and
Development firm, established in 1946 by MIT President Karl Compton and General
Georges Doriot, Harvard Business School Professor, through the US Government's effort
to spur the VC industry (Small Business Investment Companies) program, to the
practices of modem day venture capitalists. The commitments to the Venture Capitals are
shown in Figure 10. Figure 11 shows that the majority of the investors in Venture Capital
funds, are institutional investors, like pension funds and corporations. [Gompers, 2001]
Counitments to the Venture Cital Industry (billions of 1999 dollar)
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Note. Commitments are defined as the amount of money that is pledged to U.S. venture capital funds
in that year.
Soure: Venture Economics and Asset Alternatives.
Figure 10: Venture Capital Industry Commitments
(Source: Gompers, 2001)
P-- --;--·-aiaL_1 - ~I_
-··- ·~
*~ r
I ,
--- "- --
Smnmary Stadatiis for Venture Capital Fubsg by Independent Venture
Nmnber of fnd 27 147 1 34 84 204
Size (billioma of 19W9 5) 153 6.01 5.93 L09 4AQ 37-46
Prvate presion hinds 31% 20% 27% 25$% 8% 9%
Pubc peroion funds 5% 12% 17% b 9%
Crponzows 17% 12% 10% 4% 2% 16%
1 kn#dW #Watw portflwards as ivf
Nr1 4al war p 68% 78% 80%
in 2000M, there woere 1228 fnds raed with to comaited capital of $67.7 bill on.
"Public pension funds are intdud wi" private pension funds in dhest years.
Thi serii diFed iffreny in different yca. In enai yem•, the VeWn Cfdiaowen i stats that
non4ntk SRCs and publily traded tentur fands ae included with independent enture patnerrhip
In other yws. these hfad arq ctwotd in other catrgorirs It is not aailable fr 1979 and after 1994.
Sem Compiled fIet the unpoblished Veture icoeomics fnds datubse and mrio, iu"es of the
¼Vaiture Ciooopifiss The numbers dtiffer sighdy from Imenr and Gompers (199) Is to continuing
emendatons to the fus databas•
Figure 11: Source of Venture Capital Funds (Source: Gompers, 2001)
According to Fred Dotzler' at De Novo Ventures, a leading medical device investor, the
five major activities of a venture capitalist are:
* Solicit or create investment opportunities
* Evaluate companies
* Negotiate the terms of investments
* Help build successful companies
* Liquidate investments
From the start-up's perspective, according to a survey done by Dotzler, the most
important area where venture capitalists add value was "in the arena of advice and
introductions for financing". This includes advice on the amount of money to raise, the
timing of investment, and which investors to target. The next most important area is to
"help in establishing and reviewing the company's strategic focus". Other important
areas where VC's provide value is in recruiting management, being a sounding board to
CEOs and having "a strong sense of when a company is ready and market condition are
favorable to complete an IPO" and "whether to sell a company as a path to liquidity".
The Medical device Industry is also very dependent on venture capital investments for
bringing forth technologies, from concept to first clinical use and the regulatory process,
to product commercialization. Thus, a testable hypothesis is that the value of start-up
_
companies is dependent on "smart money" investors.
According the Q3 2005 "Venture Capital Investment in Health Industries Report"8 ,
Medical Devices account for about 9% of all venture capital investments (Figure 12)
Figure 12: Percentage of Venture Capital Investments in Health Care (Source: MoneyTree Survey)
kiaaii misad
1 7ir3hasd 1
Tu06w md
gum2U%
Venture Investments, in general, were severely curtailed after the dot com bubble burst in
2000. Figure 13 shows the historical pattern of VC investment in the broader health care
industries [MoneyTree Survey, 2005]. According to the report, Medical Device
investments have seen an increase of 11% in Q3 2005, compared to the same period in
the previous year.
Figure 13: Historical Pattern of VC investments in Health Care (Source: MoneyTree Survey)
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Exit Options for Medical Device Start-ups
David Strupp Jr. recently authored an article in Nature, about the change being seen in
the Biotechnology space "Success has been typically defined by the ability to maintain
independence as a publicly traded company. In this sense, it is interesting to compare the
biotech industry to the medical device industry. Unlike in the biotech industry, in the
medical device industry, a successful exit is defined as a sale to one of the large-cap
companies. Although there are many notable exceptions, the sale of a biotech company
has most often been associated with failure, not success. This is changing.... An M&A
exit will likely become more common and both the investors and the management teams
should begin to define success by the sale of the company."
In Medical Devices, the preferred exit option generally has been through a sale to a larger
medical device company. This has to do with the long and costly road to full
development, and the high risks associated with regulatory oversight and
commercialization. Figure 14[The Lewin Group, AdvaMed 2004] shows the IPO market
and M&A activity for medical devices from 1997-2003.
The IPO exits for Medical Devices came drastically down from the high of the mid to late
1990s, to completely dry up n 2003. Since then there have been a few more IPO's each
year but, not at the previous levels. The M&A exit has been a more reliable way for
medical device start-ups and their investors to get to their liquidity event. There is "a
feeling that M&A is less risky, less complicated, and takes less time to conclude than a
comparable IPO- coupled with less interest on the part of venture capitalists generally to
sever on the board of a public company in view of today's liability issues"' .
The increased number of acquisitions evident in this space, perhaps, reflects the
Mergers & Acquisitions Transaction Volume Initial Public Offerings of Venture-Backed Medical Device Finns
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acceptance by large companies that internal R&D development cannot take replace
innovative and nimble start-ups. Start-up companies that are facing tougher challenges to
go public, have to figure out their exit strategy- whether it is through an acquisition, an
IPO, or even an acquisition after an IPO. A testable hypothesis is whether companies
that get acquired post IPO get a higher valuation that those that directly move toward an
acquisition.
Corporate Venture Capital
Corporations also invest in start-ups, through a form of venture capital termed Corporate
Venture Capital (CVC). Corporate Venture Capital has seen dramatic shifts in
investment patterns. CVC investing was at its peak in 2000, when quarterly investments
rose from $468 MM at the end of 1998 to $6.2 BN in early 2000. After the economy
turned, however, quarterly investing tumbled to $848 MM, and one third of the
companies stopped making these investments". Since "CVC's are dependent on surplus
cash on the balance sheet of the parent corporation... CVC activity has cycled through
economic conditions with more volatility than the cycles seen in traditional VC 12.
Generally, at least the stated primary objective of a company engaged in corporate
venturing is strategic in nature; with financial returns an important, but secondary
motivation. Chesbrough lays out a framework to think about CVC, which is summarized
in Figure 15
Figure 15: CVC Investment Rationale (Source: Chesbrough, 2002)
Corpororate Growing Your Current Businesses
investment
objective Investment Type
strategic financial Promoting In start-ups making products Driving
a stanndard i
tight
Link to
operational
capability
loose
adoption of a technology stan-
dard you own or are backing
Stimulating In startups developing Enabling
demand complementary products
and services that increase
demand fbryour own
Leveraging In ommpanies you have spun Emergent
underutilized off in order to commercialize
technology an unused and nonstategic
technology
A corporate VC investment is defined by two characteristics: its objective and the degree
to which the operations of the investing company and the start-up are linked. Objective
can be strategic (increase sales and profits of the corporation's own business), or
financial, "a corporation seeks to do as well as or better than private VC investors, due to
what it sees as its superior knowledge of markets and technologies, its strong balance
sheet, and its ability to be a patient investor".
The second defining characteristic of CVC, according to Chesbrough, is the degree to
_ ----------- .~ ---- --- - I ~-- -~'--·----
which start-up is linked to the investing company's current operational capabilities. (Use
of company's manufacturing plants, distribution channels, technology, or brand etc).
Companies that have investments that fit the "Passive" category are generally the ones
that leave the field in the time of a downturn. This category is a version of the
discredited conglomerate model that prevailed in the 60's. The investment types with
more "staying power" are the Driving and Enabling types, while Emergent investments,
Chesbrough postulates, should be used by companies in economic boom times.
From the start-up's perspective, an investment from a corporation could grant the
technical know how, market knowledge and resources, and a potential interest in
acquisition down the line. In addition the investment could give additional credibility in
the eyes of would-be suitors, employees and other investors. This leads us to a
hypothesis that having CVC investment would raise the valuation at acquisition for the
start-up.
Hypotheses
The following factors are hypothesized to have an effect on the value of an acquisition of
a medical device start up.
Size and Experience of Venture Capital Investors
VC's are a high cost source of capital. Entrepreneurs still approach VC's for funding
their companies, because of the additional value added by the "Smart money" that has
been detailed in an earlier section. It is noted that while returns for the VC industry on
the whole is not different than returns on the S&P 500, there are specific firms and funds
that have persistently high returns for their investors.
Hypothesis 1: Companies with investing firms with larger capital under management, and
with more experience (prior rounds of investment) are associated with higher deal values.
Investment by Corporate Venture Capital
Corporations invest in start-ups primarily for strategic reasons. Investments by
companies currently in the industry could signal potential interest in an acquisition or
some validation of the concept.
Hypothesis 2: Companies in which Corporations have invested as CVC's are associated
with higher deal values.
Staging of Investments and Development of Enterprise
Gompers' 3 explains the importance of project governance in VC investing in start up
companies, due to the asymmetric information. To minimize potential agency costs,
VC's use control mechanisms including the staging of capital infusions. As the firm
develops from an early stage start-up completing set milestones, the investors fund
successively more rounds of investment.
Hypothesis 3: The Valuation of the firm is positively associated with more rounds of VC
investments, the total amount of investments and the number of years since the first
venture investment
Syndication of Investment
Lernerl 4 has documented that syndication is commonplace in VC investments. One of the
rationales for the syndication is to have a more robust screening process. Earlier studies"5
have shown investments made only if several independent observers agree, may be
superior to ones in which projects are funded after one affirmative decision.
Hypothesis 4: The number of investors is associated with a higher deal value.
Intellectual Property
The cornerstone of a life science company is its intellectual property. [Nicola 16, 2006]. A
strong IP position that gives the company the freedom to operate, and the ability to
exclude others, would be much more valuable to Investors.
The metric of the number of patents is obviously a very weak measure of the strength of
the IP of a company. A single patent, that has strong claims, can be much stronger than a
dozen weakly worded patents. In addition, I am not accounting for licenses to patents
that a company may have obtained. Having acknowledged these weaknesses, I chose to
use the number of patents assigned to, as an objective measure that I was able obtain for
all the targets.
Hypothesis 5: The number of patents assigned to the company is associated with a higher
deal value.
Capital Markets
Valuation of start-ups, at acquisition, is fundamentally linked to the broader capital
markets, as the acquiring corporations themselves are valued in the public markets. As
discussed earlier in the section on medical devices, the sector has strongly outperformed
the general market over the past few years (CAGR of 14% versus growth rates of less
than 4% for the NADAQ and S&P 500). However, some of the major acquirers in this
space are not included in the DJ Medical Equipment index, and hence I have also
included the broader indices for the analysis.
Hypothesis 6: The deal value is associated with higher NASDAQ composite levels,
S&P 500 and Dow Jones Medical Equipment (Developed world) index.
Corporate Governance and Transparency
When a company accesses the public markets for capital, there are many requirements
imposed on it by the Securities Exchange Commission (SEC) that serves to increase the
transparency of the company's operations, and reduce the problem of information
asymmetries for potential acquirers.
Hypothesis 7: Valuation of a public company would be higher than that of a privately
held company.
The Hypotheses are summarized in Figure 16.
Figure 16: Hypotheses Summary
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Methods and Data Sources
To identify the acquisitions in the device space, I used the VenturXpert (Venture
Economics) database. Other databases that also contained data, but not limited to venture
backed companies were Recap (Recombinant Capital), which had especially relevant data
for biotech deals, and MedTrack. Data on the characteristics of the start up companies
and the funding investors were taken using Thomson Financial SDC Platinum interface to
query the VenturXpert's Mergers and Acquisitions database.
The deals were chosen according to the following criteria:
Announcement of Deal: Between January 1998 and April 2006.
Industry classification: Venture Economics Industry sub groups under Medical
Diagnostics (5100), Medical Therapeutics (5200) and Medical Health Products (5300).
Where the transaction value was disclosed
There were 100 deals that satisfied these criteria. I then removed deals that included
duplicate entries, and deals on which additional information (for example investment
amounts and dates) was unavailable. From the SDC interface I retrieved data on the
Target Name, Acquirer Name, Date of Announcement, Name of Venture Funds and
Firms, the capital under management, the number of rounds of investment that the
company completed, the number of years since the company first received venture
investment, the investment made in each round of the company and the total investment
in the company. I used the US Patent Office database to query the number of patents
that were assigned to the Target prior to the announcement of the deal. From the US
Department of Labor's Bureau of Labor Statistics website I obtained the historical
Consumer Price Index and adjusted the transaction values, and the amount invested at
each round in the company to constant 2006 dollars. Using the Datastream service, I
obtained stock index levels (NASDAQ composite, S&P 500 and Dow Jones Medical
Equipment (Developed World) indices).
I used SAS Project R and JMP software for statistical analysis. The actual number of
data-points used for analysis was 90 deals.
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Figure 17: Subgroups of Acquired Companies
Among the 90 deals, there were 46 companies in the "Medical Therapeutics" group, 28 in
the "Medical Diagnostic" group and 16 in the "Medical/Health Products" groups. (See
Appendix for list of deals) The diversity of the industry is indicated by Figure 17 (b),
which shows that the companies can be divided further into 17 categories. Surgical
Instrumentation and Equipment accounted for the largest number of target companies.
Even within these categories, companies may be in very different disease spaces and may
not be comparable. For example, the Surgical Instrumentation and Equipment category
included CardioThoracic systems, AFx (Guidant), Spinal Concepts and Image-guided
Neurologics, companies in three very different disease areas. A preliminary regression
analysis showed that the valuation was not significantly correlated to the VE groups, and
subgroups.
The characteristics of companies that were successfully acquired is shown in Figure 18
(N=90). Investors in the field generally talk about a ball park of $150 MM at exit for a
Mean Median Std Dev Max Min
Transaction Value (Constant 2006 $) ($MM) $ 147 $ 91 $ 207 $1,291 $ 0.4
Total Investment (Constant 2006 $) ($MM) $ 36 $ 29 $ 34 $ 191 $ 0.3
Years since first investment 5.6 5.3 3.3 16.9 0.7
Number of Investors 6.2 5.0 4.2 18.0 1
Number of investing rounds 4.5 4.0 3.0 11.0 1
Valuation to Investment ratio (Unadjusted) 25.4 3.8 116.8 1053.0 0
Valuation to Investment ratio (Constant 2006 $) 22.7 3.54 103.9 936.7 0.03
Number of Patents 15.1 7.0 20.5 86.0 0
Corporate Venture Capital Public Company
29% 17%
Figure 18: Characteristic of Targets at Acquisition
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medical device company. The dataset that I analyzed bears that rule of thumb out, with
an average acquisition valuation of $147 MM. The Median deal value was, however,
lower at $91 MM, and the data had a large range reflected by the high standard deviation
of $207 MM. The maximum deal value was $1.29 Billion and the minimum $ 400,000.
On average, it took a company slightly under six years from the date of first investment,
with an additional round of investment every 1.2 years, to get acquired. The acquired
company had, on average, six separate investors financing about $36 MM of successive
investments and obtaining more than 15 US patents. The vast majority (83%) of the
acquired companies that were still venture backed, had not gone public, and slightly less
than 29% of these companies were backed by Corporate Venture Capital. (All Dollar
values have been converted to Constant 2006 dollars).
The average multiple of total investment was skewed by a few outliers, to 22.7 X while
the median was 3.54 X, after adjusting for inflation. Unadjusted, the median multiple was
3.8X.
I ran a multiple regression of the inflation adjusted transaction value ($MM) as the
dependent variable, with the following independent variables:
Hypothesis Metric
1 Max. size of investing firm
1 Rounds Experience of Investor
2 Corporate Venture Capital?[Yes]
3 Inftl. Adj total investmt ($MM)
3 Num. of investing rounds
3 Years since first investment
4 Number of Investors
5 Number of Patents
6 Dow Jones Med Eq
6 NASDAQ Composite
6 S&P 500
7 Target Current Public Status[Public]
Results
Figure 19 summarizes the impact of the different factors on the valuation of the Target
Statistically Significant?
Term Estimate P Value At 95% CL At 70% CL
Target Current Public Status[Public] (44.77) 0.13 No Yes
Corporate Venture Capital? [Yes] 30.78 0.22 No Yes
Years since fist investment 29.72 <.0001 Yes Yes
Number of Investors (10.07) 0.21 No Yes
Num. of investing rounds (5.64) 0.56 No No
Infl. Adj total investmt ($MM) 0.891 0.27 No Yes
Dow Jones Med Eq 0.354 0.20 No Yes
Number of Patents 0.305 0.78 No No
NASDAQ Composite 0.025 0.76 No No
Max. size of investing firm 0.012 0.015 Yes Yes
Rounds Experience of Investor (0.001) 0.57 No No
S&P 500 (0.001) 1.00 No No
Figure 19: Regression Analysis Parameter Estimates
company at acquisition. I have identified in bold-italics or bold, the factors whose
estimates were statistically significant at 95% Confidence Interval and 70% Confidence
Interval respectively. The model had an R squared of 37% and an adjusted R squared of
27%.
A complete report on the regression analysis is shown in Figure 20.
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DF Sum of Squares
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77 2406895.9
Mean Square
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31258
Figure 20: Regression Analysis Output
Report
F Ratio
3.7413
Prob > F
C. Total 89 3810271.9 0.0002
Parameter Estimates
Term
Intercept
Infl. Adj total investmt ($MM)
Years since first investment
Target Current Public Status[Private]
Number of Investors
Num. of investing rounds
Max. size of investing firm
Rounds Experience of Investor
Corporate Venture Capital?[No]
NASDAQ Composite
S&P 500
Dow Jones Med Eq
Number of Patents
Estimate
-182.0012
0.8913742
29.724994
44.770677
-10.06867
-5.639671
0.0119638
-0.001101
-30.77662
0.025468
-0.000722
0.353719
0.3045963
Std Error
248.3374
0.806436
6.91227
29.55487
7.970353
9.715376
0.003625
0.00192
24.71425
0.083111
0.352912
0.271251
1.085376
t Ratio
-0.73
1.11
4.30
1.51
-1.26
-0.58
3.30
-0.57
-1.25
0.31
0.00
1.30
0.28
Prob>ltl
0.4659
0.2725
<.0001"
0.1339
0.2103
0.5633
0.0015.
0.5681
0.2168
0.7601
0.9984
0.1961
0.7797
Effect Testsi
Source
Infl. Adj total investmt ($MM)
Years since first investment
Target Current Public Status
Number of Investors
Num. of investing rounds
Max. size of investing firm
Rounds Experience of Investor
Corporate Venture Capital?
NASDAQ Composite
S&P 500
Dow Jones Med Eq
Number of Patents
Noarm Sum of Souares F Ratio Prob > F
1
1
1
1
1
1
1
1
1
38189.79
578054.48
71729.16
49883.32
10533.07
340431.64
10275.78
48474.54
2935.19
0.13
53154.41
2461.81
1.2217
18.4928
2.2947
1.5958
0.3370
10.8909
0.3287
1.5508
0.0939
0.0000
1.7005
0.0788
0.2725
<.0001"
0.1339
0.2103
0.5633
0.0015T
0.5681
0.2168
0.7601
0.9984
0.1961
0.7797
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Discussion
The overall model had an adjusted R squared of 27%. This is comparable to the
explanatory power of a previous study 17 that looked at licensing deals in the biotech
space. Given the fact that I considered a diverse group of companies and sub-categories,
and since I did not take into account market dynamics of specific companies, including
market size, growth, nature of competition, technology and the like, (discussed in the
next section), the explanatory power of the model was surprising high.
Arnold et al, in their study in Nature in 2002 titled "Value Drivers in Licensing deals"
commented that "46-68%... (of the variability in deal value)... cannot be accounted for
by defined quantitative criteria" They then hypothesize that "manager perceptions
regarding ...quality of management, and scientists, business strategies.., and negotiation
skills" could additionally explain the variability.
In the same study, the statistical significance of the factors were divided into p<0.5,
p<0.3, and p>0.3. I have adopted the same confidence levels (95% and 70%) in this
study.
Below, I discuss each of the Hypotheses that we had formed and the results of the
analysis.
Smart Money- Hypothesis 1: Companies with investing firms that have larger capital
under management, and with more rounds of experience are associated with higher deal
values:
Result: Companies that have investors with larger capital under management were
significantly (p=0.015) correlated with higher valuation at acquisition. (Regression
parameter estimate 0.012). Each additional $100 MM dollars of capital that the largest
investor in the company has under management, the acquisition value is expected to go
up by $1.2 MM. The experience of the investors, as measured by the rounds of
experience, was not significantly correlated with higher valuation in this sample.
Corporate Venture Capital- Hypothesis 2: Companies in which Corporations have
invested as CVC's are associated with higher deal values:
Result: The analysis showed that companies with investments by corporations had a
higher (Estimated A: $30.78MM) observed acquisition prices. The association was
significant at a confidence level of 78%
Investment Staging- Hypothesis 3: The Valuation of the firm is positively associated
with more rounds of VC investments, the total amount of investments and the number of
years since the first venture investment:
Result: The valuation of companies was positively correlated to the years since the first
investment, with a parameter estimate of 29.7 (A= $29.7 MM for each year since
funding) and the effect was highly statistically significant (p<0.001). The valuation was
also slightly positively correlated with the total investment in the company (Parameter
Estimate: 0.89) at a confidence level of 73%. The effect of the number of investing
rounds was not statistically significant.
Investor Syndicate- Hypothesis 4: The number of investors is associated with a higher
deal value:
Result: One of the two surprising results in this study was that the number of investors
was negatively correlated with the valuation of the firm at acquisition. The negative
impact was moderately high (parameter estimate: 10.07; ie A= ($10) MM for each
additional investor)), at a confidence level of 79%.
Explanations for this surprising finding are not obvious. Most VC's in a syndicate would
agree to be represented on the company board by one or two lead investors, and this
practice would seem to rule out the lack of cohesive direction for the company as a
tenable explanation. One explanation could be that companies in which the original
investors had stopped funding at some point may obtain investments from other VC's in
subsequent rounds.
Intellectual Property- Hypothesis 5: The number of patents assigned to the company is
associated with a higher deal value.
Result: The effect of the number of patents on the acquisition value was not statistically
significant. As I mentioned earlier, this could be because the number of patents assigned
is a weak measure of the Intellectual Property of the company.
Capital Markets Level- Hypothesis 6: The deal value is associated with higher NASDAQ
composite levels, S&P 500 and Dow Jones Medical Equipment (Developed world) index.
Result: The acquisition valuation was positively impacted by the DJ Medical Equipment
index (Parameter estimate: 0.354) at a confidence level of 80%. The impact of the
broader indices (S&P 500 and NASDAQ) was not statistically significant.
Corporate Governance- Hypothesis 7: Valuation of a public company would be higher
than that of a privately held company.
Result: The second surprising result of my analysis was that public companies had a
statistically significant (87% confidence level) negative impact [A= $(44.7) MM if
public], on the deal value. Explanations for this may be that corporations do not pay a
premium for corporate governance systems which they would have to replace in most
cases, and the lack of transparency may tend to make corporations overpay for their
private targets, compared to the public ones.
Limitations
This study has the following limitations:
* By the very nature of the inclusion criteria through which I selected the
companies that were acquired by other companies, I am analyzing only companies
that were, in some measures, successful. According to AdvaMed (referenced in
the medical device start-up section), there were more than 4,300 companies that
had less than 100 employees. The vast majority of these companies will not
succeed in going public or getting acquired, and I have not included those
companies in this study. In effect, this analysis is looking at the characteristics of
"successful" start-ups and the impact of different factors on the extent of success
as measured by the valuation.
* [Arnold et al, 2002] surveyed a panel of manager on the relative importance of
specific value drivers in licensing deals, as perceived by licensing managers.
They were: Market (including market size, potential, patient population), Stage in
development of product, Strategy and competition as the four most important
factors biotech deals. That analysis found that only the type of partner, stage of
development, scope, and type of deal had a significant effect on the alliance, and
further reported that these factors only accounted for 32% to 52% of the
variability in deal value. In the present study, I have not considered any of these
factors explicitly. The factors that I chose revolved around the financing of the
venture, and the IP assets of the company. These factors were able to account for
27% of the variability in the data set.
* The Analysis, by design, is looking at only venture backed firms.
* For the IP assets of the start-up, I have considered only the number of patents
assigned to them. To improve the analysis, we could consider the number of
independent claims, as well as a more detailed analysis of the IP position vis-a-vis
the competition in the field.
Conclusion
In this paper, I have done the following:
* Compiled database on venture backed device deals from different sources, for
analysis.
* Researched background material on Venture Capital , Corporate Venture Capital,
Medical Device Industry and regulations
* Laid out characteristics of successful start-ups in the medical device space from a
financing and IP perspective
* Formed hypotheses and ran regression analysis to prove or disprove the thesis.
The analysis agreed with conventional wisdom for the most part. The mean value at
acquisition (in Constant 2006 $) was about $147 MM, however, the median value was
lower at $91 MM, reflecting the outlier effect of a few large acquisitions. The median
valuation at acquisition was 3.8 times the total investment in the firm, in nominal terms
and 3.5 X, inflation adjusted. The regression analysis coefficients and confidence levels
can aid companies in assessing their own potential exit values, if they succeed in getting
acquired.
The two factors that had a surprising impact on valuation were the Target's public status
and the number of investors. Private companies were on average, associated with a
higher deal value than public companies (p value= 0.13). This went against the
hypothesis that companies that had already gone public would attract higher valuations
because of better governance systems and transparency. The second surprising result was
that the number of investors was negatively associated with the valuation (p value=0.21).
Further studies would be helpful to investigate whether these two results are an anomaly
or not.
Based on this study, I conclude that start-up companies should carefully review options
regarding their investors and the stage to which they develop technologies before
acquisition. The impact of smart money, as shown by larger firms with more money
under capitalization, was highly statistically significant. Having a corporate investor
funding the company, gives it more credibility and potential access to the larger
company's resources, and, in my analysis, is associated with a significantly higher
valuation.
The broader capital market did not seem to impact the valuation, but the sector-specific
Dow Jones Medical Equipment Index was positively correlated to the price companies
were willing to pay for an acquisition. Thus timing of the acquisition is also important to
the valuation.
In this study the effect of the number of patents was not shown to be statistically
significant. This analysis can be improved by more granular measures of Intellectual
Property of the target.
Companies try to balance the potential for a higher value at exit with the risks and costs
of further development. In this analysis, the years since first investment had a
statistically significant impact on valuation. This suggests that companies that may have
breakthrough technologies should develop their products significantly from technology
development through clinical trials toward commercialization, before pursuing
opportunities for getting acquired. A future study that reviews the valuation of medical
device companies by the stage of development or commercialization, at the time of
acquisition would be useful for companies to make this decision.
P_ _-
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APPENDIX: DEAL LIST
List of medical device deals from VenturXpert, announced January 1998 to April 2006.
Transaction values shown in this list are actual values, not adjusted for inflation.
Deal # Date Target Name Acquiror Name Transaction Value
Announced ($ MM)
10/10/2005 Accellent, Inc.
6/22/2001 Accumetrics, Inc.
1/22/2004 AFx, Inc.
9/15/1999 Alliance Imaging Inc
12/16/2005 Animas Corporation
8/9/2002 Appriva Medical, Inc.
7/1/2004 Atto Bioscienc
11/9/2000 Avail Medical Products, Inc.
12/23/1998 Ballard Medical Products
5/14/2002 BEI Medical Systems Company, Inc.
2/9/1999 Biometric Imaging, Inc.
9/2/1998 BioStar, Inc.
7/7/2000 Cadent Medical Corporation
6/29/2001 Cardiac Pathways, Inc.
8/30/1999 CardioThoracic Systems, Inc.
11/29/2001 Chattanooga Group, Inc.
3/28/2002 Circe Biomedical, Inc.
8/23/2005 Clinical Pathology Laboratories, Inc.
8/6/1999 CoCensys, Inc.
7/26/2005 Consolidated Vision Group, Inc.
10/3/2005 Control Delivery Systems, Inc.
12/15/2005 CorSolutions Medical, Inc.
12/16/2002 CryoGen, Inc.
2/12/2001 DEKA Medical, Inc.
1/12/1999 Dialysis Centers of America, Inc.
10/3/2003 EBM Solutions, Inc.
9/15/1999 Ecton, Inc.
2/22/2001 Embolic Protection, Inc.
2/11/2002 Endologix, Inc
12/19/2001 Endonetics, Inc.
5/30/2002 Enteric Medical Technologies, Inc.
5/3/2003 EpiCor Medical, Inc.
7/26/1999 Exogen, Inc.
7/24/2000 First Medical, Inc.
7/24/2000 Gamera Bioscience Corporation
3/31/2004 Gelifex Inc.
6/23/1998 Hawk Medical Supply, Inc.
8/26/2005 Image-Guided Neurologics
8/30/2000 Implant Innovations, Inc.
11/24/2003 Implex Corporation
8/4/1998 InControl, Inc.
3/17/2004 Infusion Dynamics, Inc.
11/9/1999 Innovasive Devices, Inc.
7/2/2001 InSight Health Services Corporation
9/26/2003 Integrated Vascular Systems
Kohlberg, Kravis, Roberts & Co.
Radiometer A/S
Guidant Corporation
Kohlberg, Kravis, Roberts & Co.
Johnson & Johnson
MICROVENA Corporation
BD BioSciences
UBS Capital Americas II LLC
Kimberly-Clark Corporation
Boston Scientific Corporation
Becton Dickinson
Thermo Bioanalysis Corp
Cardiac Science, Inc.
Boston Scientific Corporation
Guidant Corporation
Encore Medical Corporation
ICN Pharmaceuticals, Inc.
Sonic Healthcare Ltd
Purdue Pharma L.P.
National Vision Inc
pSiVida Ltd
Matria Healthcare Inc
American Medical Systems, Inc.
Microtek Medical, Inc.
Renal Care Group, Inc.
HealthGate Data Corporation
Acuson Corporation
Boston Scientific Corporation
Radiance Medical Systems Inc
Medtronic, Inc.
Boston Scientific Corporation
St. Jude Medical, Inc.
Smith & Nephew Inc
Sigma-Aldrich Corp
Tecan AG
Synthes, Inc.
McKesson Corporation
Medtronic, Inc.
Biomet, Inc.
Zimmer Holdings Inc
Guidant Corporation
Zoll Medical Corp
Johnson & Johnson
Investor Group
Abbott Laboratories
-Continued on next page-
1,270.00
9.70
45.00
821.60
518.00
80.00
25.00
94.00
761.30
95.63
85.00
28.90
24.75
115.00
315.85
37.00
26.00
300.00
9.48
88.00
104.00
445.00
40.00
11.90
98.31
0.38
40.00
75.00
28.12
67.00
35.00
185.00
67.35
55.00
10.00
15.00
154.00
68.00
175.00
108.00
116.81
6.60
83.09
255.69
65.00
-Continued from previous page-
Deal # Date Target Name Acquiror Name Transaction Value
Announced ($ MM)
12/14/2004 InterScope Technologies, Inc.
1/5/2001 IntraTherapeutics, Inc.
2/16/2005 Ischemia Technologies, Inc.
2/20/2001 LXN Corporation
9/15/2005 Medical Metrx Solutions
1/21/2000 Medtrex
6/7/1999 Metra Biosystems, Inc.
12/14/2004 Microline, Inc.
11/5/2002 MicroNet Medical
1/13/1998 Mobile Technology, Inc.
9/27/2004 Molecular Staging, Inc.
8/15/2002 MQ Associates, Inc.
12/12/2005 National Imaging Associates, Inc.
6/7/1999 NeoPath, Inc.
3/1/2004 Novacept, Inc.
10/14/2003 Oculex Pharmaceuticals, Inc.
4/4/2000 Optical Resources Group, Inc.
9/6/2004 Opus Medical, Inc.
5/26/2005 Pathology Partners, Inc.
10/19/2000 Percusurge, Inc.
12/15/2003 Percutaneous Valve Technologies, Inc.
7/21/2004 Physicians Dialysis, Inc.
4/25/2003 Prism Enterprises, Inc.
10/18/2001 Pro-Duct Health, Inc.
2/9/2005 Proxima Therapeutics, Inc.
6/7/2002 ReGen Biologics, Inc.
9/28/2001 Rehab Associates
5/10/1999 ReSound Corporation
4/14/2005 Rubicon Medical Corporation
3/20/2006 SightLine Technologies, Ltd.
4/15/1999 SMT Health Services, Inc.
6/2/2003 Spinal Concepts, Inc.
6/28/2002 Spinal Dynamics Corporation
7/21/2004 SpineCore, Inc.
2/14/2001 Survivalink Corporation
10/25/1998 TheraTech, Inc.
2/21/2002 Timm Medical Technologies, Inc.
8/11/2003 TransVascular, Inc.
12/13/2004 US Labs, Inc.
2/15/2005 Velocimed, Inc.
3/1/2006 Venetec International, Inc.
2/13/2002 Visualization Technology, Inc.
3/13/2001 VitalCom, Inc.
7/5/2005 Vivant Medical, Inc.
9/28/2004 X-Ceptor Therapeutics, Inc.
Trestle Corporation
SulzerMedica
Inverness Medical Innovations, Inc.
Inverness Medical Innovations, Inc.
AIG Alteris Health
Johnson & Johnson (Ethicon Endo-Surgery)
Quidel Corp.
Pentax Corp
Advanced Neuromodulations Systems, Inc.
Alliance Imaging, Inc.
Qiagen N.V.
J.P. Morgan Partners
Magellan Health Services Inc
AutoCyte, Inc.
Cytyc Corporation
Allergan, Inc.
Hoya Corp
ArthroCare Corporation
Caris Ltd
Medtronic, Inc.
Edwards Lifesciences Corp
DaVita, Inc.
CooperSurgical, Inc.
Cytyc Corporation
Cytyc Corporation
Aros Corp.
Benchmark Medical, Inc.
GN Great Nordic Ltd
Boston Scientific Corporation
Stryker Corp
Alliance Imaging, Inc.
Abbott Laboratories
Medtronic, Inc.
Stryker Corp
Cardiac Science, Inc.
Watson Pharmaceuticals, Inc.
Endocare, Inc.
Medtronic, Inc.
Laboratory Corporation of America Holdings
St. Jude Medical, Inc.
CR Bard Inc
GE Medical Systems
Data Critical Corporation
Valleylab, Inc.
Exelixis Inc
1.17
145.00
24.00
29.30
21.90
7.40
22.73
48.00
5.72
100.00
28.50
350.00
122.00
107.50
325.00
230.00
76.21
90.00
120.00
225.00
125.00
150.00
23.00
167.45
160.00
14.40
5.48
185.37
99.25
50.00
105.80
170.00
269.50
120.00
79.86
312.69
33.63
60.00
155.00
82.50
166.00
50.00
10.69
66.00
23.80
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